Wang Ping, Wang Meilin, Li Sanqiang, Ma Lingjun, Xi Shoumin, He Jing
The Key Laboratory of Pharmacology and Medical Molecular Biology, Medical College, Henan University of Science and Technology, Luoyang 471023, China.
The Molecular Medicine Key Laboratory of Liver Injury and Repair, Medical College, Henan University of Science and Technology, Luoyang 471023, China.
Dis Markers. 2016;2016:4585484. doi: 10.1155/2016/4585484. Epub 2016 Nov 7.
The () gene encodes a negative regulator for p53, and the polymorphism SNP285 in the promoter region of gene has been implicated in cancer risk, but individual published studies had inconclusive results. Therefore, we performed this meta-analysis to obtain a more precise estimation between SNP285 polymorphism and risk of cancer. A systematic literature search was performed using the PubMed, Embase, and Chinese Biomedical (CBM) databases. Ultimately, 16 published studies comprising 14,573 cases and 9,115 controls were included. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess the strength of associations. Overall, SNP285 polymorphism was significantly associated with a decreased overall cancer risk with the heterozygous model (OR = 0.89, 95% CI = 0.79-0.99), and reduced ORs were observed with other genetic models (dominant: OR = 0.90, 95% CI = 0.79-1.01 and allele comparison: OR = 0.91, 95% CI = 0.80-1.03) but not reaching statistical significance. Stratification analysis indicated a decreased risk for ovarian cancer, Caucasians, and studies with relatively large sample size. Despite some limitations, this meta-analysis indicated that the SNP285 polymorphism was associated with a decreased cancer risk, which warrants further validation in large and well-designed studies.
（）基因编码一种p53的负调节因子，该基因启动子区域的单核苷酸多态性SNP285与癌症风险有关，但个别已发表的研究结果尚无定论。因此，我们进行了这项荟萃分析，以更精确地评估SNP285多态性与癌症风险之间的关系。使用PubMed、Embase和中国生物医学文献数据库（CBM）进行了系统的文献检索。最终，纳入了16项已发表的研究，包括14573例病例和9115例对照。计算合并比值比（OR）和95%置信区间（CI）以评估关联强度。总体而言，SNP285多态性与杂合子模型下总体癌症风险降低显著相关（OR = 0.89，95% CI = 0.79 - 0.99），在其他遗传模型（显性模型：OR = 0.90，95% CI = 0.79 - 1.01；等位基因比较：OR = 0.91，95% CI = 0.80 - 1.03）下观察到OR降低，但未达到统计学显著性。分层分析表明卵巢癌、白种人以及样本量相对较大的研究风险降低。尽管存在一些局限性，但这项荟萃分析表明SNP285多态性与癌症风险降低有关，这值得在大型且设计良好的研究中进一步验证。
